Video

The Number of Women Having Strokes is Rising

Preventative Mastectomy

Cases of Gestational Diabetes Are On the Rise

Nintendo Wii Could Be Therapy for Stroke Victims

Single Men Have An Increased Risk for Stroke

Fatty Foods Could Lead to Stroke in Older Women

Woman Gives Birth After Ovary Transplant

Cancer Foundation Raises Money for Neuroblastoma

Too Much Weight Gain During Pregnancy Could Lead to Diabetes

New CT Scanners Use 90% Less Radiation

Music Education Can Shape a Child's Sensory System

Food Warning Labels Could Help Prevent Choking Hazards

Acupuncture May Relieve Depression in Pregnant Women

The Economy Could Lower Life Expectancy

HPV Can Be Studied On Dolphins

Folotyn Approved for Aggressive Type of Non-Hodgkin's Lymphoma

Posted on 09/25/2009, 10:51
By -- Scott Roberts

For those who have relapsed or haven't responded to other therapies

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

More news in Lymphoma...

BigHealthTree.com Disclaimer

Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.

Rating: 3.0 / 5 (225 votes)